Topera is a venture-backed medical device company that has developed a novel 3D analysis and mapping system—the RhythmView WorkStation and FIRMap diagnostic catheter—to help electrophysiologists identify electrical sources of complex cardiac arrhythmias such as atrial fibrillation, atrial flutter, and ventricular tachycardia. The company plans a 2013 commercial launch of RhythmView and FIRMap in Europe and the U.S. Proceeds from the financing will primarily support that planned commercial launch and further advance Topera’s R&D pipeline and clinical development program. Topera’s RhythmView Workstation is 510(k) cleared by the FDA; the FIRMap Catheter is pending 510(k) clearance and is not available for sale, and CE marks for both products are pending. The company completed a $25 million Series C financing to fund these efforts. The article cites a sizeable market opportunity, noting the global market for atrial fibrillation ablation devices was approximately $2.5 billion in 2012 and that an estimated 6–7 million people worldwide suffer from atrial fibrillation.

Total raised

$25M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2013